{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:55:36Z","timestamp":1784037336714,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-024-00979-7","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T22:02:24Z","timestamp":1730152944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery \u2013 A Modeling Approach"],"prefix":"10.1208","volume":"26","author":[{"given":"Min","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-7663","authenticated-orcid":false,"given":"Guohua","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"2","key":"979_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/d41573-024-00001-x","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. 2023 FDA approvals. Nat Rev Drug Discov. 2024;23(2):88\u201395. https:\/\/doi.org\/10.1038\/d41573-024-00001-x.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"979_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/d41573-023-00001-3","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. 2022 FDA approvals. Nat Rev Drug Discov. 2023;22(2):83\u20138. https:\/\/doi.org\/10.1038\/d41573-023-00001-3.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"979_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/d41573-022-00001-9","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard A. 2021 FDA approvals. Nat Rev Drug Discov. 2022;21(2):83\u20138. https:\/\/doi.org\/10.1038\/d41573-022-00001-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"979_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/d41573-021-00002-0","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. 2020 FDA drug approvals. Nat Rev Drug Discov. 2021;20(2):85\u201390. https:\/\/doi.org\/10.1038\/d41573-021-00002-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"979_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/d41573-020-00001-7","volume":"19","author":"A Mullard","year":"2020","unstructured":"Mullard A. 2019 FDA drug approvals. Nat Rev Drug Discov. 2020;19(2):79\u201384. https:\/\/doi.org\/10.1038\/d41573-020-00001-7.","journal-title":"Nat Rev Drug Discov"},{"key":"979_CR6","unstructured":"Thomas D MA, LaFever S. Clinical development success rates and contributing factors 2011\u20132020. 2021. Available from: https:\/\/go.bio.org\/rs\/490-EHZ-999\/images\/ClinicalDevelopmentSuccessRates2011_2020.pdf."},{"issue":"2","key":"979_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nrd3375","volume":"10","author":"J Arrowsmith","year":"2011","unstructured":"Arrowsmith J. Trial watch: phase III and submission failures: 2007\u20132010. Nat Rev Drug Discov. 2011;10(2):87. https:\/\/doi.org\/10.1038\/nrd3375.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"979_CR8","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"J Arrowsmith","year":"2013","unstructured":"Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011\u20132012. Nat Rev Drug Discov. 2013;12(8):569. https:\/\/doi.org\/10.1038\/nrd4090.","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"979_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison RK. Phase II and phase III failures: 2013\u20132015. Nat Rev Drug Discov. 2016;15(12):817\u20138. https:\/\/doi.org\/10.1038\/nrd.2016.184.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"979_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","volume":"18","author":"H Dowden","year":"2019","unstructured":"Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495\u20136. https:\/\/doi.org\/10.1038\/d41573-019-00074-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"979_CR11","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","volume":"12","author":"D Sun","year":"2022","unstructured":"Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022;12(7):3049\u201362. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.002.","journal-title":"Acta Pharm Sin B"},{"key":"979_CR12","unstructured":"Di EHKaL. Chapter 19 - Pharmacokinetics. In: Edward H. Kerns LD, editors. Drug-like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization. San Diego: Academic Press; 2016. pp. 228\u201341."},{"issue":"5","key":"979_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/jcph.2185","volume":"63","author":"G An","year":"2023","unstructured":"An G, Katz DA. Importance of Target-Mediated Drug Disposition (TMDD) of small-molecule compounds and its impact on drug development-example of the class effect of HSD-1 inhibitors. J Clin Pharmacol. 2023;63(5):526\u201338. https:\/\/doi.org\/10.1002\/jcph.2185.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"979_CR14","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/bdd.1912","volume":"35","author":"G An","year":"2014","unstructured":"An G, Liu W, Katz DA, Marek GJ, Awni W, Dutta S. Population pharmacokinetics of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. Biopharm Drug Dispos. 2014;35(7):417\u201329. https:\/\/doi.org\/10.1002\/bdd.1912.","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"979_CR15","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/jcph.1925","volume":"61","author":"N Wu","year":"2021","unstructured":"Wu N, Katz DA, An G. A target-mediated drug disposition model to explain nonlinear pharmacokinetics of the 11beta-Hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 in healthy adults. J Clin Pharmacol. 2021;61(11):1442\u201353. https:\/\/doi.org\/10.1002\/jcph.1925.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"979_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/bcp.12131","volume":"76","author":"DH Wright","year":"2013","unstructured":"Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, et al. Pharmacokinetic-pharmacodynamic studies of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. Br J Clin Pharmacol. 2013;76(6):917\u201331. https:\/\/doi.org\/10.1111\/bcp.12131.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"979_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/dmd.117.078824","volume":"46","author":"J Gong","year":"2018","unstructured":"Gong J, Hansen L, Iacono L. Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, Healthy Subjects. Drug Metab Dispos. 2018;46(3):316\u201325. https:\/\/doi.org\/10.1124\/dmd.117.078824.","journal-title":"Drug Metab Dispos"},{"key":"979_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2438","author":"X Yuan","year":"2024","unstructured":"Yuan X, An G. Characterizing the nonlinear pharmacokinetics and pharmacodynamics of BI 187004, an 11beta-Hydroxysteroid dehydrogenase type 1 inhibitor, in humans by a target-mediated drug disposition model. J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1002\/jcph.2438.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"979_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cts.12618","volume":"12","author":"S Bellaire","year":"2019","unstructured":"Bellaire S, Walzer M, Wang T, Krauwinkel W, Yuan N, Marek GJ. Safety, pharmacokinetics, and pharmacodynamics of ASP3662, a novel 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, in healthy young and elderly subjects. Clin Transl Sci. 2019;12(3):291\u2013301. https:\/\/doi.org\/10.1111\/cts.12618.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"979_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/jcph.531","volume":"55","author":"G An","year":"2015","unstructured":"An G, Liu W, Dutta S. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384. J Clin Pharmacol. 2015;55(10):1079\u201385. https:\/\/doi.org\/10.1002\/jcph.531.","journal-title":"J Clin Pharmacol"},{"key":"979_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2185","author":"G An","year":"2022","unstructured":"An G, Katz DA. Importance of target-mediated drug disposition (TMDD) of small-molecule compounds and its impact on drug development - example of the class effect of HSD-1 inhibitors. J Clin Pharmacol. 2022. https:\/\/doi.org\/10.1002\/jcph.2185.","journal-title":"J Clin Pharmacol"},{"key":"979_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","volume":"51","author":"M Rowland","year":"2011","unstructured":"Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol. 2011;51:45\u201373. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100540.","journal-title":"Annu Rev Pharmacol"},{"issue":"6","key":"979_CR23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","volume":"39","author":"Y Cao","year":"2012","unstructured":"Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39(6):711\u201323. https:\/\/doi.org\/10.1007\/s10928-012-9280-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"979_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1023\/a:1018943613122","volume":"10","author":"B Davies","year":"1993","unstructured":"Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093\u20135. https:\/\/doi.org\/10.1023\/a:1018943613122.","journal-title":"Pharm Res"},{"issue":"3","key":"979_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jps.22811","volume":"101","author":"C Hall","year":"2012","unstructured":"Hall C, Lueshen E, Mosat A, Linninger AA. Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. J Pharm Sci. 2012;101(3):1221\u201341. https:\/\/doi.org\/10.1002\/jps.22811.","journal-title":"J Pharm Sci"},{"key":"979_CR26","unstructured":"Murphrey MB, Quaim L, Rahimi N, Varacallo M. Biochemistry, Epidermal Growth Factor Receptor. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Lamisa Quaim declares no relevant financial relationships with ineligible companies. Disclosure: Nader Rahimi declares no relevant financial relationships with ineligible companies. Disclosure: Matthew Varacallo declares no relevant financial relationships with ineligible companies. 2024."},{"key":"979_CR27","unstructured":"The Human Protein Atlas.\u00a0[cited 2024 8\/21]; Available from: https:\/\/www.proteinatlas.org\/ENSG00000097007-ABL1\/tissue."},{"key":"979_CR28","unstructured":"The Human Protein Atlas.\u00a0[cited 2024 8\/21]; Available from: https:\/\/www.proteinatlas.org\/ENSG00000132155-RAF1\/tissue."},{"issue":"10","key":"979_CR29","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1016\/j.xphs.2019.05.028","volume":"108","author":"RR D'Cunha","year":"2019","unstructured":"D\u2019Cunha RR, Murry DJ, An G. Nilotinib alters the efflux transporter-mediated pharmacokinetics of afatinib in mice. J Pharm Sci. 2019;108(10):3434\u201342. https:\/\/doi.org\/10.1016\/j.xphs.2019.05.028.","journal-title":"J Pharm Sci"},{"issue":"1","key":"979_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1208\/s12248-015-9836-3","volume":"18","author":"Y Bi","year":"2016","unstructured":"Bi Y, Deng J, Murry DJ, An G. A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans. AAPS J. 2016;18(1):228\u201338. https:\/\/doi.org\/10.1208\/s12248-015-9836-3.","journal-title":"AAPS J"},{"key":"979_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejps.2018.02.004","volume":"117","author":"S Bae","year":"2018","unstructured":"Bae S, D\u2019Cunha R, Shao J, An G. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice. Eur J Pharm Sci. 2018;117:27\u201334. https:\/\/doi.org\/10.1016\/j.ejps.2018.02.004.","journal-title":"Eur J Pharm Sci"},{"key":"979_CR32","unstructured":"D\u2019Cunha RR. Treatment strategies to reverse efflux transporter-mediated resistance to tyrosine kinase inhibitors [Thesis]: University of Iowa; 2018."},{"issue":"2","key":"979_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/aps.2016.107","volume":"38","author":"SR Zhang","year":"2017","unstructured":"Zhang SR, Zhu LC, Jiang YP, Zhang J, Xu RJ, Xu YS, et al. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. Acta Pharmacol Sin. 2017;38(2):233\u201340. https:\/\/doi.org\/10.1038\/aps.2016.107.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"979_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s10637-006-5269-2","volume":"24","author":"J Li","year":"2006","unstructured":"Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs. 2006;24(4):291\u20137. https:\/\/doi.org\/10.1007\/s10637-006-5269-2.","journal-title":"Invest New Drugs"},{"issue":"11","key":"979_CR35","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","volume":"11","author":"R Iyer","year":"2010","unstructured":"Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11(11):1943\u201355. https:\/\/doi.org\/10.1517\/14656566.2010.496453.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"979_CR36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","volume":"61","author":"AV Kamath","year":"2008","unstructured":"Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008;61(3):365\u201376. https:\/\/doi.org\/10.1007\/s00280-007-0478-8.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"979_CR37","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.drudis.2018.06.010","volume":"23","author":"DA Smith","year":"2018","unstructured":"Smith DA, van Waterschoot RAB, Parrott NJ, Olivares-Morales A, Lave T, Rowland M. Importance of target-mediated drug disposition for small molecules. Drug Discov Today. 2018;23(12):2023\u201330. https:\/\/doi.org\/10.1016\/j.drudis.2018.06.010.","journal-title":"Drug Discov Today"},{"issue":"3","key":"979_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/clpt.1994.134","volume":"56","author":"G Levy","year":"1994","unstructured":"Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994;56(3):248\u201352. https:\/\/doi.org\/10.1038\/clpt.1994.134.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"979_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/jcph.804","volume":"57","author":"G An","year":"2017","unstructured":"An G. Small-molecule compounds exhibiting Target-Mediated Drug Disposition (TMDD): A minireview. J Clin Pharmacol. 2017;57(2):137\u201350. https:\/\/doi.org\/10.1002\/jcph.804.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"979_CR40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jcph.1545","volume":"60","author":"G An","year":"2020","unstructured":"An G. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 2020;60(2):149\u201363. https:\/\/doi.org\/10.1002\/jcph.1545.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"979_CR41","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/jcph.1763","volume":"61","author":"G An","year":"2021","unstructured":"An G, Lee KSS, Yang J, Hammock BD. Target-mediated drug disposition-a class effect of soluble epoxide hydrolase inhibitors. J Clin Pharmacol. 2021;61(4):531\u20137. https:\/\/doi.org\/10.1002\/jcph.1763.","journal-title":"J Clin Pharmacol"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00979-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00979-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T17:02:46Z","timestamp":1732294966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00979-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00979-7","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"112"}}